Leducq, Sophie <br/><br/>
Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.  [electronic resource] 

 -  Trials  Dec 2019 
 - 739 p.  digital 
<br/><br/> Publication Type: Clinical Trial Protocol; Journal Article 
<br/><br/><label>ISSN: </label>1745-6215 
<br/><br/><label>Standard No.: </label>10.1186/s13063-019-3767-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Cutaneous<br/>Adolescent<br/>Adult<br/>Child<br/>Clinical Trials, Phase II as Topic<br/>Dermatologic Agents--administration & dosage<br/>Double-Blind Method<br/>France<br/>Humans<br/>Lymphangiectasis--drug therapy<br/>Lymphatic Abnormalities--drug therapy<br/>Multicenter Studies as Topic<br/>Quality of Life<br/>Randomized Controlled Trials as Topic<br/>Sirolimus--administration & dosage<br/>Skin Diseases--drug therapy<br/>TOR Serine-Threonine Kinases--metabolism<br/>Treatment Outcome<br/>Young Adult